FUNDAMENTALS |
MarketCap: |
13 829 mill
|
EPS: |
2.47
|
P/E: |
56.26
|
Earnings Date: |
Apr 30, 2024 |
SharesOutstanding: |
99.51 mill
|
Avg Daily Volume: |
0.880 mill
|
RATING
2024-04-24 |
S
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Strong Buy
|
|
DE: |
Buy
|
|
P/E: |
Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 56.26 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
1.18x
|
Company: PE 56.26 | industry: PE 47.78
|
DISCOUNTED CASH FLOW VALUE |
$242.24
(74.31%)
$103.27
|
Date: 2024-04-25
|
Expected Trading Range (DAY) |
$ 134.80 - 143.15
( +/- 3.00%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-04-15 | Benevich Eric | Buy | 12 587 | Common Stock |
2024-04-15 | Benevich Eric | Buy | 7 231 | Common Stock |
2024-04-15 | Benevich Eric | Sell | 12 587 | Common Stock |
2024-04-15 | Benevich Eric | Sell | 7 231 | Non-Qualified Stock Option |
2024-04-15 | Benevich Eric | Sell | 12 587 | Non-Qualified Stock Option |
INSIDER POWER |
21.05
|
Last
100 transactions |
Buy:
793 011 | Sell:
504 436 |
Forecast:
16:00 - $138.95
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $138.95
Forecast 2: 16:00 - $138.95
Forecast 3: 16:00 - $138.95
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$138.97 (-0.80% )
|
Volume |
0.850 mill
|
Avg. Vol. |
0.880 mill
|
% of Avg. Vol |
96.61 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For NBIX
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | sell | $134.47 | N/A | Active |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.